サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429904

ファーマコゲノミクスの世界市場レポート 2024

Pharmacogenomics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ファーマコゲノミクスの世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ファーマコゲノミクスの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.5%の年間複合成長率（CAGR）で134億8,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、高齢化の増加、慢性疾患の増加、総人口の増加、がん治療の需要の増加などの要因に起因すると考えられます。予測期間中に予想される主な動向には、先進治療のより詳細な解析のためのゲノム編集ソリューションの発売、遺伝子データの解析のためのゲノミクスにおける人工知能（AI）の統合への注目、メタゲノミクスの継続的な進歩、市場プレイヤー間の戦略的パートナーシップとコラボレーション、遺伝子発現と機能への影響を研究するための3次元（3D）ゲノミクスの導入、感染症と遺伝子編集に焦点を当てた新製品のイノベーション、情報に基づいた意思決定のための向精神薬ゲノミクス検査の開発などが含まれます。

高精度医療に対する需要の高まりが、ファーマコゲノミクス市場の拡大を促進しています。特定の患者サブセットに合わせた個別化された治療に焦点を当てたヘルスケアモデルである精密医療は、特に腫瘍学などの先進分野で注目を集めています。その応用範囲は、末期疾患を超えて、まれな遺伝的疾患にも及びます。精密医療は、遺伝情報と環境情報を統合して、特定の病気や反応に合わせた治療法を提供することを目指しています。 2022年 3月のリンチピンセオの記事は、今後5年間で大手製薬会社による精密医療への投資が1/3増加することを示しています。 3,000万人の2型糖尿病患者が診断および治療されている米国では、精密医療が個別化された治療を提供し、現在の診療を再構築しています。高精度医療に対する需要の高まりが、ファーマコゲノミクス市場を推進する主な原動力となっています。

ファーマコゲノミクス市場は、慢性疾患の有病率の増加により成長が見込まれています。慢性疾患は長期間にわたって持続し、世界の健康上の重大な課題を引き起こします。 ファーマコゲノミクスは、薬物反応に影響を与える個人の遺伝的差異を考慮した、個別化された治療アプローチを提供します。世界保健機関の2023年 9月の報告書によると、世界中の年間死亡者数4,100万人のうち74%が非感染性疾患（NCD）または慢性疾患によるものです。心血管疾患、がん、慢性呼吸器疾患、糖尿病がこの負担に大きく寄与しています。慢性疾患の増加傾向は、ファーマコゲノミクス市場を推進する主な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のファーマコゲノミクス市場、技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 次世代シーケンス
  • ポリメラーゼ連鎖反応
  • ゲル電気泳動
  • 質量分析法
  • マイクロアレイ
  • その他の技術
  • 世界のファーマコゲノミクス市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 神経内科
  • 創薬
  • 腫瘍学
  • 心臓病学
  • 疼痛管理
  • その他の用途
  • 世界のファーマコゲノミクス市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院と診療所
  • 研究機関
  • 学術機関

第7章 地域および国の分析

  • 世界のファーマコゲノミクス市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のファーマコゲノミクス市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ファーマコゲノミクス市場の競合情勢
  • ファーマコゲノミクス市場の企業プロファイル
    • Illumina Inc
    • Eurofins Scientific
    • Myriad Genetics Inc
    • PerkinElmer Inc
    • Centogene NV

第31章 その他の大手および革新的な企業

  • Invitae Corporation
  • Genomind
  • Pacific Biosciences of California Inc
  • Oneome LLC
  • Admera Health
  • MapMyGenome
  • Positive Bioscience
  • Xcode Life Sciences
  • Xcelris Labs
  • Takeda Pharmaceutical Company Limited
  • Garvan Institute of Medical Research
  • 3D Medicines Inc
  • Berry Genomics
  • BGI
  • GenomiCare Biotechnology

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14875

Pharmacogenomics is a research field that explores how a patient's genes influence their response to medications. Its ultimate goal is to assist doctors in selecting the most appropriate drugs and doses tailored to each individual. Pharmacogenomics is instrumental in developing personalized drugs to address various health conditions, including cardiovascular disease, Alzheimer's disease, cancer, and asthma. The term 'pharmacogenomics marker' refers to a precise medical treatment approach for individuals or specific groups.

Key technologies employed in the pharmacogenomics market include next-generation sequencing (NGS), polymerase chain reaction, gel electrophoresis, mass spectrometry, microarray, and others. NGS, a massively parallel sequencing technology, offers ultra-high throughput, scalability, and speed, enabling the determination of nucleotide order in entire genomes or specific DNA/RNA regions. Pharmacogenomics applications span neurological diseases, infectious diseases, oncology, cardiovascular diseases, pain management, and various other areas. End-users encompass hospitals and clinics, research institutions, academic institutes, and others.

The pharmacogenomics market research report is one of a series of new reports from The Business Research Company that provides pharmacogenomics market statistics, including pharmacogenomics industry global market size, regional shares, competitors with a pharmacogenomics market share, detailed pharmacogenomics market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacogenomics industry. This pharmacogenomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pharmacogenomics market size has grown rapidly in recent years. It will grow from $8.14 billion in 2023 to $9.04 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The expansion observed in the historical period can be attributed to robust economic growth in emerging markets, a growing emphasis on personalized medicine, the development of advanced healthcare infrastructure, and an increase in healthcare expenditure.

The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $13.48 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The anticipated growth in the forecast period can be attributed to factors such as the increasing aging population, a rise in chronic diseases, a growing overall population, and an increasing demand for cancer treatment. Key trends expected in the forecast period include the launch of genome editing solutions for a more in-depth analysis of advanced therapies, a focus on integrating artificial intelligence (AI) in genomics for the analysis of genetic data, continuous advancements in metagenomics, strategic partnerships and collaborations among market players, the introduction of three-dimensional (3D) genomics to study influences on gene expression and function, new product innovations with a focus on infectious diseases and gene editing, and the development of psychotropic pharmacogenomics tests for informed decision-making.

The growing demand for precision medicine is fueling the expansion of the pharmacogenomics market. Precision medicine, a healthcare model focused on personalized treatment tailored to specific patient subsets, is gaining traction, especially in advanced areas such as oncology. Its applications extend beyond late-stage diseases to encompass rare and genetic conditions. Precision medicine aims to integrate genetic and environmental information to tailor treatments for specific diseases and responses. A Linchpinseo article from March 2022 indicates a 1/3 increase in precision medicine investment by leading pharmaceutical companies over the next five years. In the USA, where 30 million people with type 2 diabetes are diagnosed and treated, precision medicine offers individualized treatment, reshaping current practices. The rising demand for precision medicine is a key driver propelling the pharmacogenomics market.

The pharmacogenomics market is expected to experience growth due to the increasing prevalence of chronic diseases. Chronic diseases, persistent over an extended period, pose a significant global health challenge. Pharmacogenomics provides a personalized treatment approach, considering individual genetic variations influencing drug responses. According to the World Health Organization's September 2023 report, non-communicable diseases (NCDs) or chronic diseases account for 74% of the 41 million annual deaths worldwide. Cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this burden. The upward trend in chronic diseases is a major factor propelling the pharmacogenomics market.

A noteworthy trend in the pharmacogenomics market is technological advancement. Medicine manufacturers are actively pursuing various approaches to pharmacogenomics analysis, aiming to offer cost-effective solutions for screening known polymorphisms and discovering novel variants. In May 2021, Integrated Prescription Management (IPM), a U.S.-based pharmacy benefits management (PBM) company, collaborated with Myriad Genetics Inc. to launch the GeneSight test. This pharmacogenomics testing solution targets patients dealing with depression or anxiety, showcasing technological advancements in precision medicine.

Companies in the pharmacogenomics market are concentrating on the development of innovative solutions for infectious disease diagnosis and gene editing to fortify their market standing. For instance, in March 2022, Thermo Fisher Scientific Inc., a U.S.-based supplier of analytical instruments and life sciences solutions, introduced the latest generation of its SeqStudio Flex Series Genetic Analyzer. This innovative tool, leveraging Capillary Electrophoresis (CE) technology, enhances research in infectious disease diagnosis and gene editing. The SeqStudio Flex Genetic Analyzer, available in 8- and 24-capillary configurations, delivers high-quality data and reliable performance across various applications.

In June 2023, Genomenon, a U.S.-based genomics intelligence company, acquired Boston Genetics for an undisclosed amount. This strategic acquisition combines Genomenon's AI-powered genomic platform with Boston Genetics' genetic scientists to comprehensively curate the human genome. The acquisition strengthens clinical diagnostic and pharmaceutical drug development programs by providing valuable insights into the genomic drivers of genetic diseases and oncology. Additionally, it establishes a genomics data service arm for Genomenon, offering cost-effective variant curation team extensions for genetic testing labs, expediting turnaround times. Boston Genetics, a genomics interpretation and curation company based in the U.S., is part of this acquisition.

Major companies operating in the pharmacogenomics market report are Illumina Inc., Eurofins Scientific, Myriad Genetics Inc., PerkinElmer Inc., Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc., Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc., Berry Genomics, BGI, GenomiCare Biotechnology, Biotecan Pharmaceuticals, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, Future Science Group, QIAGEN N.V, Institute of Biomedical Chemistry, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, AnorMed, 23andMe, Myriad Genetics, Color Genomics, Pathway Genomics, Laboratorio Richet, Laboratorio Exame, Genomika Diagnosticos, Gulf Pharmaceutical Industries JULPHA, Neopharm, NewBridge Pharmaceuticals Limited, EIPICO (Egyptian International Pharmaceutical Industries Company), Aspen Pharmacare Holdings Limited, Pharma-Q (Pty) Ltd

North America was the largest region in the pharmacogenomics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharmacogenomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The pharmacogenomics market includes revenues earned by entities by PennCNV,QuantiSNP, GenoCN and Nexus.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmacogenomics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmacogenomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharmacogenomics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharmacogenomics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Technology: Next Generation Sequencing; Polymerase Chain Reaction; Gel Electrophoresis; Mass Spectrometry; Microarray; Other Technologies
  • 2) By Application: Neurological Diseases; Infectious Diseases; Oncology; Cardiovascular Diseases; Pain Management; Other Applications
  • 3) By End User: Hospitals and Clinics; Research Institutions; Academic Institutes; Other End Users
  • Companies Mentioned: Illumina Inc; Eurofins Scientific; Myriad Genetics Inc; PerkinElmer Inc; Centogene N.V
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pharmacogenomics Market Characteristics

3. Pharmacogenomics Market Trends And Strategies

4. Pharmacogenomics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Pharmacogenomics Market Size and Growth

  • 5.1. Global Pharmacogenomics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pharmacogenomics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pharmacogenomics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pharmacogenomics Market Segmentation

  • 6.1. Global Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Gel Electrophoresis
  • Mass Spectrometry
  • Microarray
  • Other Technologies
  • 6.2. Global Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Neurology
  • Drug Discovery
  • Oncology
  • Cardiology
  • Pain Management
  • Other Applications
  • 6.3. Global Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals And Clinics
  • Research Institutions
  • Academic Institutes

7. Pharmacogenomics Market Regional And Country Analysis

  • 7.1. Global Pharmacogenomics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pharmacogenomics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pharmacogenomics Market

  • 8.1. Asia-Pacific Pharmacogenomics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pharmacogenomics Market

  • 9.1. China Pharmacogenomics Market Overview
  • 9.2. China Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pharmacogenomics Market

  • 10.1. India Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pharmacogenomics Market

  • 11.1. Japan Pharmacogenomics Market Overview
  • 11.2. Japan Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pharmacogenomics Market

  • 12.1. Australia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pharmacogenomics Market

  • 13.1. Indonesia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pharmacogenomics Market

  • 14.1. South Korea Pharmacogenomics Market Overview
  • 14.2. South Korea Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pharmacogenomics Market

  • 15.1. Western Europe Pharmacogenomics Market Overview
  • 15.2. Western Europe Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pharmacogenomics Market

  • 16.1. UK Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pharmacogenomics Market

  • 17.1. Germany Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pharmacogenomics Market

  • 18.1. France Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pharmacogenomics Market

  • 19.1. Italy Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pharmacogenomics Market

  • 20.1. Spain Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pharmacogenomics Market

  • 21.1. Eastern Europe Pharmacogenomics Market Overview
  • 21.2. Eastern Europe Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pharmacogenomics Market

  • 22.1. Russia Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pharmacogenomics Market

  • 23.1. North America Pharmacogenomics Market Overview
  • 23.2. North America Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pharmacogenomics Market

  • 24.1. USA Pharmacogenomics Market Overview
  • 24.2. USA Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pharmacogenomics Market

  • 25.1. Canada Pharmacogenomics Market Overview
  • 25.2. Canada Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pharmacogenomics Market

  • 26.1. South America Pharmacogenomics Market Overview
  • 26.2. South America Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pharmacogenomics Market

  • 27.1. Brazil Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pharmacogenomics Market

  • 28.1. Middle East Pharmacogenomics Market Overview
  • 28.2. Middle East Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pharmacogenomics Market

  • 29.1. Africa Pharmacogenomics Market Overview
  • 29.2. Africa Pharmacogenomics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pharmacogenomics Market, Segmentation By Applications , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Pharmacogenomics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pharmacogenomics Market Competitive Landscape And Company Profiles

  • 30.1. Pharmacogenomics Market Competitive Landscape
  • 30.2. Pharmacogenomics Market Company Profiles
    • 30.2.1. Illumina Inc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Eurofins Scientific
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Myriad Genetics Inc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. PerkinElmer Inc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Centogene N.V
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Pharmacogenomics Market Other Major And Innovative Companies

  • 31.1. Invitae Corporation
  • 31.2. Genomind
  • 31.3. Pacific Biosciences of California Inc
  • 31.4. Oneome LLC
  • 31.5. Admera Health
  • 31.6. MapMyGenome
  • 31.7. Positive Bioscience
  • 31.8. Xcode Life Sciences
  • 31.9. Xcelris Labs
  • 31.10. Takeda Pharmaceutical Company Limited
  • 31.11. Garvan Institute of Medical Research
  • 31.12. 3D Medicines Inc
  • 31.13. Berry Genomics
  • 31.14. BGI
  • 31.15. GenomiCare Biotechnology

32. Global Pharmacogenomics Market Competitive Benchmarking

33. Global Pharmacogenomics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pharmacogenomics Market

35. Pharmacogenomics Market Future Outlook and Potential Analysis

  • 35.1 Pharmacogenomics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Pharmacogenomics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Pharmacogenomics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer